Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Feb 1;199(3):381-384.
doi: 10.1164/rccm.201809-1631LE.

IL-1 Blockade Reduces Inflammation in Pulmonary Arterial Hypertension and Right Ventricular Failure: A Single-Arm, Open-Label, Phase IB/II Pilot Study

Cory R Trankle  1 , Justin M Canada  1 , Dinesh Kadariya  1 , Roshanak Markley  1 , Horacio Medina De Chazal  1 , Janet Pinson  1 , Adam Fox  1 , Benjamin W Van Tassell  1 , Antonio Abbate  1 , Daniel Grinnan  1
Affiliations
Clinical Trial

IL-1 Blockade Reduces Inflammation in Pulmonary Arterial Hypertension and Right Ventricular Failure: A Single-Arm, Open-Label, Phase IB/II Pilot Study

Cory R Trankle et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Study results. DASI = Duke Activity Severity Index; hsCRP = high-sensitivity C-reactive protein; MLWHFQ = Minnesota Living with Heart Failure Questionnaire; pV.o2 = peak V.o2; RV = right ventricular; RVFAC = RV fractional area change; TAPSE = tricuspid annular plane systolic excursion.
See this image and copyright information in PMC

Comment in

References

    1. Huertas A, Perros F, Tu L, Cohen-Kaminsky S, Montani D, Dorfmüller P, et al. Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay. Circulation. 2014;129:1332–1340. - PubMed
    1. Pickworth J, Rothman A, Iremonger J, Casbolt H, Hopkinson K, Hickey PM, et al. Differential IL-1 signaling induced by BMPR2 deficiency drives pulmonary vascular remodeling. Pulm Circ. 2017;7:768–776. - PMC - PubMed
    1. Soon E, Holmes AM, Treacy CM, Doughty NJ, Southgate L, Machado RD, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation. 2010;122:920–927. - PubMed
    1. Voelkel NF, Tuder RM, Bridges J, Arend WP. Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. Am J Respir Cell Mol Biol. 1994;11:664–675. - PubMed
    1. Van Tassell BW, Abouzaki NA, Oddi Erdle C, Carbone S, Trankle CR, Melchior RD, et al. Interleukin-1 blockade in acute decompensated heart failure: a randomized, double-blinded, placebo-controlled pilot study. J Cardiovasc Pharmacol. 2016;67:544–551. - PMC - PubMed

Publication types

Substances